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Transcatheter aortic valve replacement (TAVR) has emerged as an alternative treatment for 
inoperable and high risk patients with severe symptomatic aortic stenosis. TAVR short and 
medium term results are very promising, however paravalvular leak (PVL) post-TAVR still 
represents a significant complication. PVL post-TAVR is shown to be an independent predictor of 
short-term and long-term mortality. Despite, its importance and prevalence, with a wide range of 
reported incidences, only few studies addressed the PVL after TAVR.  
In the present study, first, the mathematical lumped parameter model is used to model the 
simplified circulatory system in presence of PVL and to evaluate the performance of TAVR by 
computing the variation of the left ventricle stroke work (LVSW) under several pre-TAVR and 
post-TAVR conditions. Results show that in a large majority of cases, TAVR significantly reduced 
LVSW. However, in cases with pre-existing aortic stenosis conditions with trace/mild aortic 
regurgitation, it did not significantly reduce LVSW or even led to an increase. 
Second, a three-dimensional (3D) computational fluid dynamics (CFD) simulation is performed 
in order to investigate the effect of PVL on the diastolic flow-field characteristics post-TAVR.  
Results show that PVL leads to significant disturbances in blood flow, which characterized by high 
speed jets, coherent structures and markedly elevated shear stress on both sides of the implanted 
aortic leaflets, which could promote a more rapid degeneration of the valve leaflets.  
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Results could be useful in understating the hemodynamics of PVL post-TAVR and estimating 
some important parameters, which could not be obtained during the medical assessment (e.g. wall 
shear stress).  Also, they could be a help in the process of choosing the appropriate valve for TAVR 
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CHAPTER 1: Introduction 
 
1.1. Overview 
The cardiovascular system, also called the circulatory system, is an organ system that 
permits blood to circulate and provides the body with its oxygen and nutrition demands. It also 
assists in the removal of metabolic wastes. The human cardiovascular system consists of the heart 
as a pump, blood vessels and approximately five liters of blood.  The top of the heart, known as 
the heart’s base, connects to the great blood vessels of the body, including the aorta.  
The aorta is the largest vessel in the body which begins at the top of the left ventricle, the 
heart's muscular pumping chamber. The heart pumps the blood from the left ventricle into the aorta 
through the aortic valve. The function of the aortic valve is to open and close with each heartbeat 
to allow a one-way flow of blood.  This valve is known as the most important valve of the heart 
and the most commonly affected by valvular heart disease requiring heart valve replacement (Iung 
et al., 2005,Williams et al., 2010).  
There are two primary valvular heart disease processes that can affect the aortic valve: 
aortic insufficiency/aortic regurgitation and aortic stenosis (AS). AS is now the most common 
valvular heart disease in the western world (Manning, 2013). Research shows that without 
treatment, half of the people with severe AS symptoms die within an average of 2 years (Otto, 
2000). 
Medical treatment for severe symptomatic AS is not effective, and replacing the heart valve 
is considered as the only effective treatment (Bonow et al., 2006). For patients with severe 
symptomatic AS who are suitable candidates for open-heart surgery, surgical aortic valve 
replacement (SAVR) is a gold standard treatment (Bonow et al., 2006). However, it has been 
shown in practice, SAVR is denied in around 33% of elderly candidates (Iung et al., 2005). To 
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meet the medical needs of these patients who have been deemed inoperable or high-risk for 
traditional SAVR, transcatheter aortic valve replacement (TAVR) has emerged as a new 
technology over the past decade and is now being put into clinical practice. This technology has 
had significant impacts throughout the health care field with the creation of a new biotechnology 
industry around transcatheter valves and the creation of multidisciplinary “heart teams”; clinicians 
and engineers.  TAVR, however, as a new technology is still associated with some limitations and 
complications.  
This chapter will first provide an overview of the human body circulation system. 
Secondly, the anatomy and physiology of the heart valves, with emphasis on the aortic valve, are 
described. Then, aortic valve diseases, in particular, aortic stenosis are explained; to identify the 
necessity and prevalence of aortic valve replacement (AVR). It is followed by presenting and 
comparing available AVR methods: SAVR and TAVR, procedures, devices, complications and 
outcomes. Then, aortic paravalvular regurgitation (PAR) as a major current complication of TAVR 
is introduced and overviewed in detail. Finally, the objective of this thesis and proposed studies 
and methodologies are presented. 
 
1.2. Human Body Circulatory System 
The circulatory system (Figure 1-1) is powered by the heart, a four-chambered (upper 
chambers: left and right atria, lower chambers: left and right ventricles) muscular organ that acts 
as a pump. In the human body, this system consists of two connected subsystems; the systemic 
circulation and the pulmonary circulation.  
In the systemic circulation, the left ventricle pumps oxygenated blood into the aorta. The 
blood travels from the aorta to arteries and the capillary network, as well as coronary arteries. 
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There, the blood releases oxygen and takes on carbon dioxide and wastes. The deoxygenated blood 
is then collected in veins and travels to the right atrium and into the right ventricle.  
 
 
Figure 1-1; Humans circulatory system (Adopted from2009, Pearson Education Inc.) 
 
 
In the pulmonary circulation: the right ventricle pumps deoxygenated blood into the 
pulmonary artery, which branches off into smaller arteries and capillaries in the lung. There, the 
carbon dioxide is released from the blood and oxygen enters the bloodstream. Then, the 
oxygenated blood travels through the pulmonary vein and the left atrium into the left ventricle. 
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The next heart beat starts a new cardiac cycle of systematic circulation. Each cardiac cycle 
can be divided into two main phase (Figure 1-2): diastole and systole. Diastole represents the 
period of time when the ventricles are relaxed (no contract). Systole represents the time when the 
ventricles contract, and eject blood to the system. 
 
 
Figure 1-2:  Complete cardiac cycle (Richard E. Klabunde, 2007) 
 
1.3. Heart Valves 
Cardiac valves are structures that work like one-way doors. They let blood flow from one 
chamber or vessel to another, and then close to prevent the blood from regurgitating backward. The 
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normal human heart contains four cardiac valves that regulate blood flow into and out of the heart; 
aortic valve, pulmonary valve, mitral valve and tricuspid valve (Figure 1-3).  
 
 
Figure 1-3: Anatomy of the heart valves(Tips, 2013) 
 
1.4. Aortic Valve 
The aortic valve (Figure 1-4), the most important valve of the heart (Williams et al., 2010), 
is located at the left ventricle outflow tract where the aorta begins. As a centerpiece of the heart, it 
approximately affects many other important cardiac structures.  
The aortic valve main function is to prevent blood regurgitation from the aorta into the left 
ventricle during diastole and to allow the appropriate flow of blood, cardiac output, from the left 




Figure 1-4: Aortic valve and heart skeleton, obtained from (Robvalve, 2014) 
 
Figure (1-5) shows the detailed anatomy of the aortic valve. It consists of three important 
parts: Annulus, Cusps and Commissures.  
 Annulus: The aortic valve annulus so called aortic ring (Figure 1-5) is a crown shaped 
structure at the level of the junction of the aortic valve and the ventricular septum which provides 
support to the aortic valve complex. (Anderson, 2000; Misfeld and Sievers, 2007) . 
 
 
Figure 1-5: Anatomy of the aortic valve (Kasel et al., 2013; Sievers and Schmidtke, 2007) 
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 Cusps: There are three half-moon shaped aortic valve cusps/ leaflets (Figure 1-5); Left 
coronary cusp (LCC), right coronary cusp (RCC), and posterior or non-coronary cusp (NCC). 
(Benjamin, 2013). 
 Commissures: Each cusp is attached to the wall of the aorta by the outward edges of its 
semicircular border at the level of sinotubular junction (functional level of the aortic valve orifice).  
The small spaces between each cusp's attachment points are called the aortic valve commissures 
(see figure 1-5).  
 
1.5. Aortic Valve Stenosis 
Aortic stenosis (AS) refers to a heart disease which is usually defined by restricted opening 
of the aortic valve leaflets during systole. The stenotic aortic valve cannot open fully which causes 
a partial restriction of blood flow from the left ventricle into the aorta.  
 
 




AS is now the most common valvular heart disease in the western countries (Manning, 
2013). The presence of the significant AS increases the left ventricle pressure and cardiac workload 
which causes hypertrophy and could lead in sudden death and heart failure in case of  severe AS 
(Nishimura, 2002). 
AS may exist from birth (congenital), but most often it develops later in life.  It mainly 
occurs due to the accumulation of calcium deposits (calcification) during the time that narrow the 
valve. Calcification of the valve mostly affects older people and could happen sooner in people 
who are born with abnormal aortic or bicuspid valves. It is estimated that AS occurs in about 25% 
of people over 65 years of age (Benjamin, 2013). Another cause is rheumatic fever. This condition 
can develop after strep throat or scarlet fever which is becoming rarer in the United States.  
As the aortic valve gets stenosed and narrowed, the left ventricle has to work harder to 
pump blood throughout the valve. To do this extra work, the muscles in the ventricle walls become 
thicker, which can lead to chest pain. As the pressure continues to rise, blood may back up into the 
lungs. Severe aortic stenosis is really life threatening, and can limit the amount of blood that 
reaches the brain and the whole body.   
Treatments for aortic stenosis depend on how far the disease has progressed. Currently, 
replacing the aortic valve is considered as the only effective treatment for severe AS (Edwards 
Lifesciences Corporation, 2013, Bonow et al., 2006). 
 
1.6. Aortic Valve Replacement 
Aortic valve replacement (AVR) has been the standard of care for patients with 
symptomatic sever aortic stenosis for several decades (Bonow et al., 2006; Manning, 2013). 
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Currently, there are two AVR approaches; surgical aortic valve replacement (SAVR), and 
minimally invasive transcatheter (Percutaneous) aortic valve replacement (TAVR).  
 
1.6.1. Surgical Aortic Valve Replacement (SAVR) 
Surgical aortic valve replacement (SAVR) through open-heart surgery is a common 
treatment for severe aortic stenosis on patients who are suitable candidates for surgery (Bonow 
et al., 2006). It consists of a surgical replacement of the native calcified aortic valve with a 
prosthesis heart valve (mechanical, bio-prosthesis, homograft tissue and Ross procedure) 
(Manning, 2013).  
 
Figure 1-7: Surgical aortic valve replacement (SAVR) procedure 
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1.6.1.1. Procedure  
SAVR is most frequently done through a median sternotomy (Figure 1-7), meaning that 
the chest is surgically separated. Once the chest has been opened, the patient is put on a 
cardiopulmonary bypass machine (heart-lung machine). The surgeon replaces the native 
malfunction aortic valve with an artificial heart valve. After SAVR, the patient will frequently stay 
in an intensive care unit for 12–36 hours, and is often able to go home after this, in about four days. 
1.6.1.2. Prosthetic Heart Valves  
Prosthetic heart valves are devices that implanted in the heart of a patient  through the open 
heart surgery. Currently, there are three types of heart valves; mechanical heart valves, tissue/ 
biological heart valves and tissue engineered heart valves. This notes provides a quick overview 
on characteristics and comparison of the available prosthetic heart valves.   
 
I. Mechanical Heart Valves: Mechanical heart valves (MHV) are prosthetic valves, which 
are designed to replicate the functions of the natural human heart valves. MHVs are classified into 








Figure 1-8: Different types of mechanical heart valves:a) caged-ball valve; b) mono-leaflet tilting valve; 
c) bileaflet valve (Lori et al., 2014; Symersky et al., 2012) 
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Most of the observational studies on MHVs have shown excellent long term results with 
no difference in durability between types of prosthesis. MHVs are considered durable and mostly 
lasts for 20-30 years. However, their main weakness is that all MHVs have an absolute lifelong 
requirement for anticoagulant treatment to avoid red blood cell damage, clotting and thrombus 
formation. (Bloomfield, 2002; Pibarot and Dumesnil, 2009).  
II. Biological/ Tissue Heart Valves:  The requirement for anticoagulant treatment in 
mechanical heart valve could be avoided by a valve replacement with suitable biological material. 
Therefore, biological (tissue) heart valves are designed not only to function like natural heart 
valves ,but also to mimic the anatomy of the native valve and avoid the potential risks  of a long 
term anticoagulation therapy. Currently, tissue valves are the most used heart valves in US and 
EU.  
Depending on where and how the tissues are harvested, biological heart valves categorized 
into three main groups: autograft valves (replacing by patient’s own pulmonary valve), homograft 
valves (replacing by heart valves of brain dead human organ donor) and xenograft valves 
(harvested from pig or cow heart valves) (Bloomfield, 2002). 
 
 
Figure 1-9 : Some types of biological heart valves 
a)  Stented pericardial bovine bioprosthetic valves, Edwards. PREMOUNT magna, b) Stented porcine 
aortic valve bioprostheses, Biocore, c) Stentless bioprosthetic valve, TORONTO SPV 
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A major advantage of bioprosthetic valves is the low rate of thromboembolism (1.6 % per 
patient year). The risk of anticoagulation-related bleeding is also significantly lower.  However, 
several studies have identified that bioprosthesis have limited lifespan as some patients require 
reoperation in the fourth or fifth postoperative year (Wan and Sarvasti, 2005; Pibarot and 
Dumesnil, 2009). 
III. Tissue Engineered Heart Valves: Tissue engineered heart valves (TEHVs) are new, 
emerging alternative which offer the potential SAVR with a ‘living’ valve that resembles the shape 
and function of the native valve. TEHVs would be able to grow,  repair and remodel as a native 
valve does (Rippel et al., 2012; Vesely, 2005).  Although there is still a long way to go 
(Neuenschwander and Hoerstrup, 2004), tissue engineered heart valves give new hopes for less 
invasive procedures with the use of natural-like devices, which would decrease the risk of 
complications and improve valve performance (Rippel et al., 2012). 
 
 
Figure 1-10: Stented trileaflet heart valve scaffold (Mol et al., 2006) 




1.6.1.3. SAVR Outcome and Complications 
SAVR is both recommended by ACC/AHA and the European Society of Cardiology as a 
standard of care, and the outcomes for none-high risk suitable surgery candidates is.  SAVR 
decreases mortality, reduces symptoms, and improves patient quality of life (Clark et al., 2012).  
However, like all surgeries and treatments, there are some risks and complications associated with 
it. 
In addition, several studies have reported that prosthesis patient mismatch (PPM) is 
frequent (20% to 70%) and has a negative impact on short- and long-term outcomes after SAVR 
for aortic stenosis (AS) (Pibarot et al., 2014). 
Furthermore, even though SAVR improves symptoms and survival, observational studies 
have identified various subgroups of patients who are at increased risk for operative complications 
or death. In such patients (33% of elderly candidates) who are deemed inoperable or high risk for 
SAVR a less invasive treatment may be a suitable alternative (Clark et al., 2012; Iung et al., 2005; 
Svensson et al., 2011).  
 
1.6.2. Transcatheter Aortic Valve Replacement (TAVR)  
Transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve implantation 
(TAVI) is a fairly recent minimally invasive procedure, which is approved by the FDA as the 
standard of care for extremely high risk or inoperable patients. It is an authorized alternative to 
surgery for selected high-risk but operable patients with symptomatic AS (American Heart 
Association, 2014; Genereux et al., 2013).  There have already been over 50,000 implants in over 
40 countries since the first TAV was implanted at 2002 (Faxon, 2011; Webb and Wood, 2012a).   
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1.6.2.1. TAVR Procedure  
TAVR repairs the valve without removing the native, damaged and calcified valve. Instead, 
it expands a replacement valve into the aortic native valve location. Through TAVR procedure the 
transcatheter valve is delivered via a catheter to its place (Edwards Lifesciences Corporation, 
2014). In this procedure (Figure 1-11), a valve with a tiny balloon at the end is sent into its place. 
Then the balloon is inflated to open the native diseased valve and deflated. In the next step, the 
balloon is expanded again to open up the transcatheter valve, deflated and removed. TAVs delivery 
and positioning may be really challenging, and are not without complications (Fishbein et al., 
2013). TAVR may be performed using three different approaches, depending on which one 
provides the best and safest way to access the valve: transfemoral, transapical and transaortic. 
 
Figure 1-11 Transcatheter aortic valve replacement procedure (TAVR)(Center, 2013) 
 
1.6.2.2. Transcatheter Heart Valves  
Transcatheter heart valves (THVs) or percutaneous heart valves are a new technology of 
heart valves which represent a less invasive way for treating heart valve disease. THVs designed 
to be delivered via a catheter through the body's cardiovascular system (TAVR procedure), thus 
eliminating the need of open surgery. Currently, two THV devices are widely used: Edwards 
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SAPIEN Transcatheter Heart Valve (Figure 1-12-a), Medtronic CoreValveTM (Figure 1-12-b) 
(Généreux et al., 2015). 
 
Figure 1-12: different type of transcatheter heart valves 
a) SAPIEN (Edwards Lifesciences, Irvine, CA, USA), b) CoreValveTM (Medtronic, Minneapolis, MN, 
USA), c)Lotus valve (Boston Scientific Inc., Natick, Massachusetts), d) Direct Flow valve (Direct Flow 
Medical Inc., Santa Rosa, California), e)Acurate (Symetis Inc., Ecublens, Switzerland), f) Portico (St. 
Jude Medical Inc., St. Paul, Minnesota), g) HLT (Bracco Inc., Princeton, New Jersey), h) JenaClip 
(JenaValve Inc., Munich, Germany) 
 
Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA), 
utilizes a balloon-expandable system. It has a cobalt-chromium alloy frame with a bovine 
pericardium tri-leaflet construction. The inflow of the frame is covered with fabric to provide an 
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annular seal. This valve is available in three generations: SAPIEN, SAPIEN XT and SAPIEN 3 in 
23 mm, 26 mm and 29 mm valve sizes. 
Medtronic CoreValveTM (Medtronic, Minneapolis, MN, USA) consists of a tri-leaflet 
bioprosthetic porcine pericardial tissue valve, which is mounted in a self- expanding stent frame, 
a nickel-titanium alloy that is malleable at low temperature, but relatively rigid at body 
temperature. It is available  in  26mm, and 29mm prosthesis ( Abdel-Wahab et al., 2011).   
Currently, only limited nonrandomized studies are available which compared these two 
devices. In 2014, Iqbal and Serruys published a review study and stated that “there is a device-
specific complications between SAPIEN and CoreValve, but no difference in clinical outcomes”. 
Despite the post-TAVR results show that coronary obstruction may be more frequent with 
SAPIEN, and paravalvular regurgitation (PAR) and atrioventricular block requiring pacemaker 
implantation is more common with CoreValve, the patients treated with the CoreValve and the 
SAPIEN have been shown to have similar short- and long- term outcomes (Abdel-Wahab et al., 
2014; Eltchaninoff et al., 2011; Moat et al., 2011; Webb and Wood, 2012) 
There are also a number of newer THVs in early clinical evaluation. In general these valves 
incorporate features, which reduce delivery catheter diameter, improve ease of positioning or 
removal, and provide better sealing mechanisms to reduce paravalvular leak. For the most part, 
these next generation of valves are self-expandable (Webb and Wood, 2012a). 
• Self-expanding Lotus valve (Boston Scientific Inc., Natick, Massachusetts) (Figure1-12-c) 
• Self-expanding Direct Flow valve (Direct Flow Medical Inc., Santa Rosa, California) 
(Figure1-12-d)  
• Self-expanding Acurate (Symetis Inc., Ecublens, Switzerland) (Figure1-12-e) 
• Portico (St. Jude Medical Inc., St. Paul, Minnesota) (Figure1-12-f) 
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• HLT (Bracco Inc., Princeton, New Jersey) (Figure1-12-g) 
• JenaClip (JenaValve Inc., Munich, Germany) (Figure1-12-h) 
Although these newer valves offer many desirable features, experiences are limited. Therefore, 
clinical outcomes with the newer generations need to be evaluated. 
1.6.2.3. TAVR Outcomes and Complications 
TAVR procedure is not without risks; however it is the only available treatment for high 
risk, inoperable patients with symptomatic aortic stenosis (Généreux et al., 2013), while also 
providing the added value of a faster patient recovery in most cases (American Heart Association, 
2014).   
Experience with TAVR has increased significantly over the past several years which 
addressed TAVR procedure, outcomes and its complications. Although the trend shows that the 
clinical outcomes of TAVR have steadily improved (Webb and Wood, 2012a), TAVR is still 
associated with some  predictable and unanticipated procedural and post- procedural complications 
due to the complexity of the procedure, as well as the morbidity of the patients being treated 
(Fishbein et al., 2013; Holmes et al., 2012), such as: 
• Risk factors related to the aortic valve pathology ( paravalvular leak, aortic rupture, LV 
hypertrophy, subaortic stenosis)  
• Vascular complications  
• Renal complications 
• Coronary artery problems  




 Many research groups have stablished systematic reviews on TAVR short-term outcomes in 
comparison to SAVR or solely ; no differences in 30-day and 1-year mortality, were found among 
more than 8000 patients in 29 studies between the TAVR and SAVR (Kodali et al., 2012; Tang et 
al., 2013). However, paravalvular leak (PVL) was more significant after TAVR, and associated 
with an increase in late mortality (Mohamed Abdel-Wahab et al., 2011).  
The outcome of TAVR in high-risk patients have also been studied in single-arm and 
randomized controlled studies (Fishbein et al., 2013). In the Unites States, PARTNER  registered 
study (Craig R. et al., 2011; Leon et al., 2010; Makkar et al., 2012) demonstrated that TAVR 
maintains a sustained superiority over medical treatment in inoperable patients with symptomatic 
severe AS, significantly reduces the rates of death and hospitalization, decreases symptoms and 
improves in valve hemodynamics. This study also states that for high-risk patients, there is an 
equivalent outcomes between TAVR and SAVR.  However, elevated 50% mortality in 3-year 
among inoperable patients makes the long-term efficacy of this therapy questionable. The stroke 
and PVL remain a concern, as well as the lack of benefit of TAVR in extremely high-risk patients 
(Tang et al., 2013).  
 
1.7. Paravalvular Aortic Leak Following TAVR 
As previously stated (Section 1.6.2.3), paravalvular aortic leak (PVL) or regurgitation 
(PAR) is one the major current complication of TAVR (Dvir et al., 2013). PVL is known to be 
associated with an increase in late mortality and affect the outcomes of TAVR (Mohamed Abdel-
Wahab et al., 2011).   This does not mean that mild PVL is uncommon after SAVR, but studies 
have shown that PVL after SAVR do not have significant impact on short-term and long-term 
clinical outcomes (Rallidis et al., 1999). FRANCE 2 (Van Belle et al., 2014), European registered 
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study on 3195 patients from 34 countries reported that the presence of more than mild PVL is the 
most powerful predictor for 1 year mortality. Incidence of PVL following TAVR, including small 
non-significant jets, is estimated to be as high as 48%-85% in different studies. (Gotzmann et al., 
2012; Lerakis et al., 2013; Smolka and Wojakowski, 2010). 
 
1.7.1. Definition and Causes 
PVL refers to blood flowing back, during left ventricle filling,  through a channel between 
the structure of the implanted valve and native valve tissue (as a result of an  incomplete 
circumferential apposition of the prosthesis with the annulus)  (Sinning et al., 2013). The majority 
of PVL orifices are crescent, oval or roundish-shaped and their track can be parallel, perpendicular 
or serpiginous.  
Significant PVL or annular rupture is usually due to prosthetic under sizing or oversizing 
caused by discordance in the orthogonal diameters of oval-shaped annuli with the circular 
prosthesis (John et al., 2010). Mal-positioning of the valve or displacement of the valve may also 
cause PVL (Buellesfeld and Grube, 2012; John et al., 2010). Another risk factor for PVL is a 
functional bicuspid aortic valve.  
 
1.7.2. Presentations and Symptoms  
Clinically significant acute PVL is characterized by a considerable diastolic backflow into 
the LV leading to acute volume overload, which leads to LV pressure overload, followed by an 
increase in the LV end-diastolic volume and cardiac output.  
In acute severe PVL, the LV is unable to increase the end-diastolic volume effectively. As 
the LV fails to increase the total stroke volume, the forward stroke volume and systolic arterial 
pressure decrease (Azadani et al., 2009; Gotzmann et al., 2012).  
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Therefore, Significant PVL may lead to fatal cardiogenic shock, heart failure (HF), 
hemolytic anemia and infectious endocarditis. Hemolysis can be severe enough to precipitate 
symptoms of anemia (Pate et al., 2006; Safi et al., 2000; Smolka & Wojakowski, 2010).  
 
1.7.3. Assessments and Classifications 
The severity of PVL should be assessed by the following information (Smolka and 
Wojakowski, 2010): 
• Shape and orientation of the jet 
• Number of jets 
• Maximum velocity 
• Presence of the distal flow reversal 
• Pulmonary pressures  
The most important diagnostic modality which gives the above information is imaging, such as: 
• Angiographic assessment 
•  Echocardiography assessment [transthoracic echocardiography (TTE), transesophageal 
echocardiography (TEE)] 
• Cardiac Magnetic resonance (CMR)  
•  Multi-slice computed tomography (MSCT) 
• Intraprocedural imaging [Intravascular ultrasound (IVUS), Aortography 
While all above multiple modalities have been used to characterize PVL, echocardiography 
remains the least costly and most widely available. Currently, echocardiography should be the first 
step in a comprehensive and integrative evaluation of the post-TAVR patient. If multiple 
echocardiographic parameters confirm that PVL is severe, CMR would be advocated to more 
accurate quantitation of regurgitant fraction (Hayek, 2014). It is important to realize that 
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quantification of PVL after TAVR still remains challenging (Lerakis et al., 2013; Zoghbi et al., 
2009).  
PVL severity is not only of prognostic value but it may as well lead to therapeutic 
intervention. Therefore, it is essential to accurately characterize and categorize the severity of 
PVL, given that the patients undergoing TAVR are typically high risk. The Valve Academic 
Research Consortium (VARC) published the VARCII criteria (Table 1-1) for hemodynamic 
severity assessment of AR and/or PVL after TAVR. VARCII classifies PVL severity into three 
levels; mild, moderate and severe. However, the body of evidence supporting these criteria for the 
assessment of PVL are limited and requires further validation (Généreux et al., 2013; Kappetein 
et al., 2012).    
In addition, the current guidelines adopted by VARC-2 are arbitrary, derived from the 
evaluation of aortic regurgitation in native valves, with certain adaptations emphasizing the 
description of jet anatomy (Kappetein et al., 2012; Zoghbi et al., 2003). 
 






1.8.  Objective and Outline of This Study 
The specific aim of the present study is to develop a numerical and computational model 
to investigate: 1) The flow dynamics patterns induced in the presence of PVL; 2) The variations 
in left ventricular performance following TAVR in the presence of different severities of 
paravalvular leak.   
The results will be useful in understating the presence of PVL post TAVR and evaluating 
important parameters that cannot or are difficult to obtain in vivo (e.g. wall shear stress, oscillatory 
wall shear stress, LV stroke work).  This work will also help the process of choosing the 
appropriate THV valve for TAVR procedure, based on comparing the pre and post TAVR different 
scenarios.  
In reference to the defined objectives, in this research, two separate models are employed: 
First, the concept of mathematical lumped parameter model is used to model the simplified 
circulatory system in presence of paravalvular leak and evaluate the variation of the left ventricle 
stroke work under several pre-TAVR and post-TAVR (combinations of aortic valve stenosis and 
aortic valve regurgitation/PVL).  
Second, three-dimensional (3D) computational fluid dynamic simulations are performed 
in order to investigate the effect of paravalvular leak on the diastolic flow-field characteristics 








CHAPTER 2: Literature Review   
 
2.1. Introduction 
The cardiovascular system has always been of interest to engineers and scientists. 
Researchers have been studying its characteristics by using experimental, mathematical or 
computational methods.  Several mathematical and numerical models of the cardiovascular system 
have been introduced since 1959, when Grodins published the first global mathematical model of 
cardiac and blood vessel hemodynamics (Paeme et al., 2011). Models vary significantly in 
complexity and objectives, ranging from a simple zero-dimensional model (Westerhof et al., 
2009),  to a very complex network of representations of the vascular tree (Shim et al., 2008), three-
dimensional finite element (FEM) models (Kerckhoffs et al., 2007; Pham and Vincent, 2001),  
computational fluid dynamic (CFD) models (Schenkel et al., 2009) or even coupled (FSI) models 
(Sermesant et al., 2006).  Each model serves different uses, but they all share the common goal of 
understanding cardiovascular function and provide us with the following considerable benefits: 
• Engineering studies are non-invasive  
• They could be performed in less time and at a lower cost 
• They could provide us with some data and information that are difficult/impossible to 
measure in-vivo. 
The importance of engineering studies are not less than Trial or PARTNER studies in this area and 
they have several applications. First, they could provide additional information to support medical 
decisions. Fast and accurate models could also be used in combination with medical imaging and 
other diagnostic techniques in a clinical setting to provide real-time information to advance patient 
care. Second, these studies would help the cardiovascular equipment and tool developers, by 
validating and predicting the performance of the device, to improve the product design and 
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decrease the cost of production. The long term goal of these engineering studies is to set up a 
system of techniques and tools, which could be of help for clinical practice.  
In this work, due to the importance and prevalence of the aortic paravalvular leak (PVL) 
following transcatheter aortic valve replacement (TAVR) (described in Chapter 1), two separate 
models are employed to investigate the nature of the PVL following TAVR: 1) a zero-dimensional 
mathematical lumped parameter model and 2) a  three-dimensional computational fluid dynamic 
(CFD) model.   
2.2. Numerical Lumped Parameter Modeling 
A lumped parameter model is a mathematical model which simplifies the description of 
the behavior of the distributed physical systems into a topology consisting of discrete entities. 
Mathematically speaking, the simplification reduces the partial differential equations (PDEs) of 
the continuous (infinite-dimensional) time and space model of the physical system into ordinary 
differential equations (ODEs) with a finite number of parameters.  
The concept of lumped parameter modeling was first quantitatively formulated and 
popularized in cardiovascular studies by Otto Frank in 1899. The so called Windkessel model by 
Otto was a two-element model, which describes the hemodynamics of the arterial system in terms 
of resistance and compliance. It later extended to three-element and four-element models by 
adding the characteristic impedance (Westerhof et al., 1971, 1969), and additional inertance 
(Burattini and Gnudi, 1982), consecutively. However, the lumped model of the arterial system or 
a part of it cannot be used for wave transmission and wave travel studies as well as blood flow 
distribution; it serves to simulate the real cardiac circuit, and it is simple and fairly accurate in the 
approximation of many important parameters of this circuit, such as cardiac output and right 
ventricular afterloads (Westerhof et al., 2009). 
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Since then, many scientists have extensively employed similar concepts of lumped 
parameter modeling in order to evaluate cardiovascular system hemodynamics in different 
scenarios (Westerhof et al., 2009). In several studies, simple or coupled models (heart-arterial,  
ventricle-arterial, etc) have been used to do theoretical analysis (Kerckhoffs et al., 2007; Segers et 
al., 2003, 2002) to predict the contributions of changes in parameters, and to show that the 
predictions are supported by experimental data. These models have also been employed in 
modeling pathological conditions, such as pulmonary hypertension (Tanné et al., 2008), aortic 
stenosis (Garcia and Durand, 1983; Garcia et al., 2005a), aorta coarctation and bicuspid aortic 
valve (Keshavarz-Motamed et al., 2014b). Several studies have also been reported on the nonlinear 
models in studies on ventricular assist devices and setups to test artificial valves (Dolan et al., 
2006; Geven et al., 2004; Mol et al., 2006). 
Despite the fact that lumped parameter modeling application has been widely studied in 
the cardiovascular area, there is no study which has investigated the effect of PVL on cardiac 
output or left ventricle stroke workload by implementing the mathematical lumped parameter 
modeling method.  
 
2.3. Computational Mechanics Modeling 
Computational mechanics (CM) modeling  is concerned with the use of computational 
methods to model phenomena governed by the principles of mechanics, which usually involves 
expressing the natural or engineering system in terms of partial differential equations and solving 
them by digital computation through discretization. Different specializations within CM, including 
computational fluid dynamics (CFD), computational structural mechanics (CSM) and fluid-solid 
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interactions (FSI) have been widely used in the area of cardiovascular research and are capable of 
modeling really complex scenarios.  
Since the 70s, many CM studies have addressed the cardiovascular system in different 
aspects, starting from very simple two-dimensional symmetric models to realistic three-
dimensional dynamic analysis. In this section, a short survey will be given on the different heart 
valve CM models that have been developed over the years. The review is mainly focused on 
prosthetic heart valves. 
 
2.3.1. Computational Mechanics Modeling in Heart Valves  
One of the first contributions in this field was made in 1972 by Peskin. Peskin succeeded 
to capture the movement of two flexible solids in a 2D fluid domain using his immersed boundary 
method (Mcqueen and Peskin, 1997; Peskin and McQueen, 1989, 1980). Later, Black et al. (1991) 
was amongst the first to model a 3D geometry of a native aortic heart valve and analyze the stress-
strain distribution in the leaflets subject to pressure-load. 
Studies dealing with native valve motions have mainly been performed in two major ways: 
1) prescribing leaflet movement from experimental data, focused only on the fluid flow (Chandran 
et al., 1998; Krafczyk et al., 2001, 1998; Vino B et al., 1997); 2) employing the coupled fluid-solid 
interaction method to include both structural and fluid aspects (Cheng et al., 2004; De Hart et al., 
2003; Dumont et al., 2004; Hart et al., 2000; King et al., 1997; Lai et al., 2002; Nicosia et al., 2003; 




2.3.2.  Computational Mechanics Modeling in Prosthetic Heart Valves 
Over the past five decades a vast number of computational mechanics simulations have 
been reported in the literature on the structural modeling of prosthetic heart valves (PHVs) and on 
the computation of the flow dynamics past PHVs. Early studies were more focused on modeling 
MHVs due to their high availability and the relatively strong materials of the leaflets, which makes 
them rigid and easier to deal with. Avoiding the complications of FSI analysis, the first studies 
reported on detailed flow through MHVs with valve leaflets in the fully open position. Tilting disc 
valves (Kiris et al., 1997; Shim and Chang, 1997) and bi-leaflet valves (Bluestein et al., 2002; Ge 
et al., 2005; King et al., 1997; Shi et al., 2003) were modeled using this approach. These studies 
concentrated in regions of high velocity and turbulent shear stresses and also in regions of flow 
stagnation where activated platelets may cause subsequent embolic problems.  
More recently, several studies employing more advanced FSI analysis with moving leaflets 
for the flow past MHVs have been reported (Borazjani et al., 2008; Dumont et al., 2007, 2005, 
2004; Ge et al., 2008; Morbiducci et al., 2009).  
Studies also investigated bioprosthesis heart valves (BHVs) including transcatheter heart 
valves (THVs).  Unlike the MHVs, the BHVs leaflet material exhibits a highly non-linear, 
anisotropic behavior and undergoes large and complex deformations. The flow past the valvular 
structures results in a complex 3D time-dependent flow and both the solid and fluid dynamics must 
be accurately resolved.  
Early studies mostly reported on theoretical geometries; 2D structures or simplified 3D 
valve structures with linear material properties (Chandran, 2010). Cataloglu et al. (1977) used 
linear material assumptions, while Hamid et al. (1985) based their study on a multi-linear model. 
Huang et al. (1990) employed a 2D model with a total lagrangian approach to solve FEM equations 
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with large deformations. Christie and Medland (1982) were among the first who developed a 3D 
model with nonlinear anisotropic material relations. Later, Sanders et al. (1996) modeled a 3D 
stented bioprosthetic heart valve with nonlinear elastic behavior materials. Using nonlinear 
material properties was found to be more realistic when compared to experimental and in vivo 
results (Chandran, 2010).   
Considering more recent studies, Kim et al. (2008) carried out a 3D nonlinear dynamic 
simulation of realistic BHVs’ leaflets to investigate the nature of calcification and degradation in 
BHVs. In another study, Borazjani (2013) developed the first fully-resolved 3D BHV simulation 
under physiologic conditions without any symmetry assumption, questioning the accuracy of 
previous symmetrical simulations.  
 
2.3.3.  Computational Mechanics Modeling in Transcatheter Aortic Valves 
Dwyer et al. (2009b) performed a CFD study on a 3D transcatheter aortic valve, 
considering its degeneration and hemodynamics due to transcatheter valve (TAV) sclerosis (35% 
orifice reduction) and stenosis (78% orifice reduction). Their results showed that stenosis led to 
significant forces on TAV during systole with stress concentrations on the tips of the leaflets. 
However, diastolic forces on TAV predominated even in presence of significant stenosis. Stenosis 
also elevates the magnitude of wall shear, reaching values that could be clinically relevant to 
hemolytic injury and thrombus deposition.  
Sun et al. (2010) carried out a FSI simulation of 3D transcatheter valve deployment, 
addressing the distorted configurations of asymmetrical deployment process of the TAV into a 
calcified aortic root. Their study indicated that the distorted, elliptical TAVs induced a significant 
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increase in leaflet peak stresses and strains compared with a nominal circular TAV under the same 
boundary/loading conditions.  
In another study by Sirois et al. (2011), a 3D patient specific simulation of TAV 
deployment (FE, CFD) was performed. Their CFD model was validated where possible by 
benchmarking against TAV clinical trial data in the literature. Their analysis of the flow field gave 
insights on the velocity profile, including coronary artery flow distribution pre- and post-
deployment. It was observed that although cardiac output increases and transvalvular pressure 
decreases following TAV intervention, the amount of coronary artery flow present does not 
increase proportionally. 
Tan et al. (2011) also performed a study on flow patterns before and after TAVI, using 
combined cardiovascular magnetic resonance imaging (CMR) and CFD. A patient with aortic 
stenosis was examined using MRI pre- and post-TAVI, and 3D CFD simulations were carried out 
incorporating MRI-derived patient-specific data. Pre-TAVI velocity profiles demonstrated the 
highly disturbed turbulent flow and jet impacting the wall of the aortic arch due to the stenosed 
aortic valve. While, post-TAVI velocity profiles were similar to those in healthy aortas with 
spatially more uniform WSS and lower turbulence levels, demonstrating the effectiveness of the 
TAVI procedure in restoring normal aortic flow.  
As a step forward in the direction of creating a computational tool able to support TAVI 
preoperative planning (anticipating surgical operation outcomes),  Auricchio et al. (2013) and 
Morganti et al. (2013) performed FEM studies, modeling TAV deployment process in a few 





2.4. Engineering Studies in Prosthetic Aortic Valve Regurgitation 
Some engineering studies have addressed regurgitation and reverse flows through native 
stenotic or diseased heart valves. Only a few engineering studies have considered to simulate/ 
model the heart valve prosthesis in the presence of regurgitation.  
Hsu and Lu (2013) modeled the 3D tiling disk mechanical heart valve in the presence of 
valve regurgitation with both pulsatile and quasi-steady flow conditions. Their FSI analysis used 
an immersed moving occluder (rigid tilting prosthetic heart valve) interacting with the flow in an 
infinite straight duct as a domain during the full heart cycle. Their results also indicated that the 
steady simulations of the regurgitation is not accurate enough to describe the flow field in 
comparison to the pulsatile unsteady simulations.  
Although to the best of our knowledge there is no computational modeling research which 
has specifically considered paravalvular leak post-TAVR, a few experimental studies have been 
conducted to investigate TAV associated with PVL. Azadani et al. (2009) used the left heart 
experimental setup with implanted TAV in the aortic valve position. A TAV designed to mimic a 
23 mm SAPIEN and 3 different sizes (19, 21 and 23 mm) of Carpentier-Edwards bioprostheses. 
Their objective was to compare the energy loss due to the paravalvular leak in TAVs versus 
surgically implanted bioprosthesis. Their results suggested that, in the presence of mild PVL, TAV 
implantation imposes a significantly higher workload on the left ventricle than an equivalently 
sized surgically implanted bioprosthesis of a similar size. 
Scotten and Siegel (2014) conducted an experiment on PVL post-TAVR using a mock 
TAV device consisting of an Edwards-Perimount model 2800 pericardial surgical valve and 
adjustable lower panel PVL setting. Their results reported on comparability of thrombogenic 
potential of TAV to mechanical heart valves. 
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Transcatheter aortic valve replacement (TAVR) has recently emerged as a feasible and 
viable solution for symptomatic patients with severe aortic stenosis who are denied standard aortic 
valve replacement. TAVR short and medium term results are very promising but appear 
suboptimal in the presence of paravalvular leak. Using a mathematical model, this study simulates 
several patient conditions based on valve area and regurgitation severity before and after TAVR. 
The objective is to define the conditions that lead to suboptimal results. Pre-TAVR 
conditions include aortic stenosis effective orifice areas (EOAs) of 0.4, 0.6, 0.8 and 1.0 cm2 with 
concomitant aortic regurgitation severities ranging from trace/mild to moderate-to-severe. For 
each condition, we simulated the implantation of transcatheter aortic valves with effective orifice 
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areas of 1.3, 1.6 and 1.9 cm2 and similar ranges of paravalvular leak as pre-TAVR aortic 
regurgitation. The performance of TAVR was evaluated considering the relative change in the 
computed left ventricle stroke work (LVSW). In a large majority of cases (76%), TAVR 
significantly reduced LVSW (range: -13±8% to -84±2%). However, in 16% of cases, TAVR did 
not significantly reduce LVSW and in 9%, TAVR led to an increase in LVSW (range: +16±13% 
to 84±20%). Most of the conditions where TAVR underperformed corresponded to pre-existing 
aortic stenosis conditions with only trace/mild aortic regurgitation. In conclusion, patients with 
aortic stenosis and only trace/mild aortic regurgitation should be considered with care when 
planning for TAVR because of potential suboptimal performance despite a reduction in 




Transcatheter aortic valve replacement (TAVR) has recently emerged as a feasible and 
viable solution for patients with severe symptomatic aortic stenosis who are denied standard 
surgical aortic valve replacement because of elevated operative risks (Leon et al., 2010; Smith et 
al., 2011). TAVR short and medium term results are very promising (Genereux et al., 2013; Ussia 
et al., 2012). There remain, however, important complications lowering the benefit of TAVR in a 
certain proportion of patients (Leon et al., 2010; Smith et al., 2011; Kodali et al., 2012). The most 
important one appears to be post-TAVR paravalvular leak (PVL) (Gilard et al., 2012; Kodali et 
al., 2012). The prevalence of PVL following TAVR varies between studies and ranges from 7% 
to 70% for mild PVL and 0% to 24% for more than mild PVL severity (Pibarot et al., 2015). PVL 
has been shown to be an independent predictor of short-term and long-term mortality following 
TAVR (Abdel-Wahab et al., 2011; Tamburino et al., 2011; Moat et al., 2011). Suboptimal outcome 
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following TAVR can even be found in patients with mild to moderate PVL (Athappan et al., 2013; 
Hayashida et al., 2012). It appears therefore that under certain conditions, the benefit of TAVR in 
terms of lowering left ventricle (LV) pressure load is balanced/overcome by an increase in volume 
overload, due to PVL. It remains unclear however what specific combinations of valve EOA and 
valve regurgitation/PVL before and following TAVR will lead to a significant reduction in LV 
stroke work. For example, does implanting a transcatheter aortic valve (TAV) with an EOA of 
1.60 cm2 and mild-to-moderate PVL in a patient with a stenotic valve of 0.60 cm2 and only a 
trace/mild aortic valve regurgitation lead to a significant reduction in LV stroke work? To 
contribute towards answering this question, we developed a lumped parameter model capable of 
simulating patient conditions before and after TAVR. 
More specifically, the objectives of this study are: 1) To evaluate the variations in LV 
stroke work under several pre-TAVR and post-TAVR combinations of valve EOAs and valve 
regurgitation/PVL of various intensities; 2) Introduce an estimate for the variation in LV stroke 




A schematic diagram of the lumped parameter model is presented in Figure (3-1). This 
model includes four different sub-models. 1) left ventricle model; 2) aortic stenosis (AS) model; 
3) aortic regurgitation model; 4) systemic circulation model. In this study, our lumped-parameter 
model developed and validated by Keshavarz-Motamed et al. (2014, 2011) was modified and 




Figure 3-1: Schematic diagrams: a) schematic representation of the lumped parameter model used to 
simulate aortic stenosis with/without aortic regurgitation and transcatheter aortic valve with/without 
paravalvular leak; b) electrical representation of the model. Elv(t): normalized time-varying elastance. Rav 
and RAR/PLV represent aortic valve stenosis resistance and aortic valve paravalvular leak or regurgitation 
resistance, respectively. Lav and LAR/PLV represent aortic valve stenosis inductance and aortic valve 
paravalvular leak or regurgitation inductance, respectively.  See Table (3-1) for details. 
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3.2.1. Heart-Arterial Model 











                (1) 
Where PLV(t), V(t) and V0 are the LV pressure, the LV volume and the unloaded volume, 
respectively. The amplitude of E(t) is normalized with respect to maximal elastance Emax, giving 
EN(tN)=E(t)/Emax. Time is also normalized with respect to the time to attain peak elastance, TEmax 
(tN=t/TEmax). It has been shown that normalized time-varying elastance curves EN(tN) have similar 
shapes in normal human hearts with various inotropic situations or for diseased human hearts 












                (2) 
3.2.2. Aortic Stenosis Model 
The following formulation has been used to model instantaneous net pressure gradient 
across the stenotic aortic valve (TPGnet) (Benevento et al., 2015; Garcia et al., 2005b; Keshavarz-























               (4) 
where CoEL , EOA , A ,   and Q are the valvular energy loss coefficient, valve effective 




3.2.3. Aortic Regurgitation Model 
Aortic regurgitation and PVL were modeled following the same approach used for 
modelling aortic stenosis, except that the pressure difference (AR_TPGnet) controlling the 
regurgitant flow (QAR) is the difference between aortic pressure and LV pressure during diastole. 
Furthermore, the EOA used corresponds to a regurgitant orifice area (REOA) and the energy loss 



























_                                                                                                        (6) 
This approach has shown a very good consistency with clinical guidelines (Lancellotti et 
al., 2010), i.e., the range of REOA corresponds very well to the expected ranges in terms of 
regurgitant fraction (Rf), the ratio of backward stroke volume to forward stroke volume.  
 
3.2.4. Simulated conditions 
LV stroke work was computed under the following conditions: 
Pre-TAVR. Four different severe aortic stenosis with valve EOAs of 0.4, 0.6, 0.8 and 1.0 
cm2 have been tested. These values are consistent with in vivo data of patients who underwent 
TAVR (Ali et al., 2015; Caballero et al., 2015). For each case of severe aortic stenosis different 
levels of aortic regurgitation have been simulated: Trace/mild (Regurgitant fraction (Rf) < 15%); 
mild-to-moderate (15% < Rf < 30%); moderate (30% < Rf < 40%) and moderate-to-severe (40% 
< Rf < 50%). These levels of chronic aortic regurgitation have already been reported in patients 
with severe aortic stenosis who underwent TAVR (Amat-Santos et al., 2014; Ewe et al., 2015). 
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The classification used here is consistent with clinical practice guidelines as well (Bonow et al., 
2006; Lancellotti et al., 2010; Lerakis et al., 2013; Pibarot et al., 2015; Zoghbi et al., 2009).  
Post-TAVR. Three different valve EOAs of 1.30, 1.60 and 1.90 cm2 have been tested. 
These values are consistent within the range of in vivo data of patients who underwent TAVR 
(Clavel et al., 2011). The same levels and classification used for aortic regurgitation were used for 
PVL following TAVR, which is consistent with the existing literature (Lerakis et al., 2013; Pibarot 
et al., 2015).  




Ventricular parameters    
Unstressed volume V0 -15 mL 
Maximal elastance Emax Adjusted for stroke a net stroke volume 
of 70 mL  
Time to maximal elastance TEmax 0.24 s 
Aortic valve parameters   
Effective orifice area EOA Modified for each case 
Regurgitant orifice area REOA Modified for each case 
Aortic cross-sectional area Aao 8 cm2 
Systemic circulation parameters   
Aortic systolic pressure Ps 120 mmHg 
Aortic diastolic pressure Pd Changes with regurgitant fraction. 
Baseline value 80 mmHg 
Aortic compliance  Cao 0.5 mL/mmHg  
Systemic vein resistance   RSV 0.05 mmHg.s.mL-1  
Systemic arteries and veins compliance CSAC 2 mL/mmHg  
Systemic arteries resistance  
(including arteries, arterioles and 
capillaries)  
RSA Initial value: 0.8 mmHg.s.mL-1  
Adjusted for an aortic systolic pressure 
of 120 mmHg  
Upper body resistance Rub Adjusted to have 15% of total flow rate 
(McDonald, 1974) 
Proximal descending aorta resistance  Rpda 0.05 mmHg.s.mL-1 
Output condition   
Central venous pressure PCV0 4 mmHg 
Input condition   
Mitral valve mean flow rate  Qmv  
Other   
Constant blood density  1050 kg/m3  
Heart rate HR 70 bpm 
Duration of cardiac cycle  T  857 ms  
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Other hemodynamic conditions including heart rate, systolic pressure, baseline diastolic 
pressure and baseline stroke volume are listed in Table (3-1). Overall, a total of 128 conditions 
have been tested numerically. 
 
3.2.5. Transcatheter aortic valve replacement performance index (TAVR PI) 
 In this work, we evaluated the performance of transcatheter aortic valve implantation as 
the relative variation in LV stroke work before and after TAVR. The first approach uses the ∫𝑃 𝑑𝑣 
to compute LV stroke work (the area inside the generated p-v loops): 
 
𝑃𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 𝐼𝑛𝑑𝑒𝑥 (𝑃𝐼) = 100 ×
𝐿𝑉𝑆𝑊𝐴𝑆−𝐿𝑉𝑆𝑊𝑇𝐴𝑉
𝐿𝑉𝑆𝑊𝐴𝑆
                                                                                     (7) 
 
Where LVSWAS represents LV stroke work developed in the presence of the severe aortic 
stenosis (before TAVR) and LVSWTAV is LV stroke work developed by the LV after TAVR. Note 
that the performance index can be negative if TAVR led to an increase in LV stroke work 
compared to pre-TAVR conditions. For example, a PI of 80% means that TAVR successfully 
reduced LV work load due to severe AS by 80%. While a PI of -20% means that TAVR led to an 
increase in LV work load compared to the initial work load induced by the severe AS by 20%. 
The second approach, uses the variation of an estimate for LV stroke work. This is because 
the true value for LV stroke work cannot be determined non-invasively. The estimated LV stroke 
work is computed as the product of the LV forward stroke volume and peak LV systolic pressure. 
Peak LV systolic pressure is estimated then as the sum of systolic aortic pressure and mean 
transvalvular pressure gradient: 
𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑃𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 𝐼𝑛𝑑𝑒𝑥 (𝑃𝐼) = 100 ×
𝑆𝑉𝐴𝑆(𝑃𝑠+𝑇𝑃𝐺𝐴𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅)−𝑆𝑉𝑇𝐴𝑉(𝑃𝑠+𝑇𝑃𝐺𝑇𝐴𝑉̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅)
𝑆𝑉𝐴𝑆(𝑃𝑠+𝑇𝑃𝐺𝐴𝑆̅̅ ̅̅ ̅̅ ̅̅ ̅)




Where, SVAS is the forward stroke volume pre-TAVR; 𝑇𝑃𝐺𝐴𝑆̅̅ ̅̅ ̅̅ ̅̅  is the mean transvalvular 
pressure gradient pre-TAVR; SVTAV is the forward stroke volume post-TAVR (that can be 
different from pre-TAVR conditions depending on the severity of paravalvular leak) and 𝑇𝑃𝐺𝑇𝐴𝑉̅̅ ̅̅ ̅̅ ̅̅ ̅̅  
is the mean transvalvular pressure gradient post-TAVR. This estimation of peak LV pressure has 
already been used by our group for the evaluation of valvular-arterial impedance in the context of 
patients with aortic stenosis and systemic hypertension (Briand et al., 2005).  





Figure (3-2) shows typical flow and pressure waveforms obtained using our model for three 
different configurations: 1) aortic stenosis with EOA of 0.8 cm2, with no aortic regurgitation 
(Rf=0%) (Figure 3-2-a); 2) an implanted TAV with an EOA of 1.60 cm
2 and no paravalvular leak 
(Rf =0%) (Figure 3-2-b); 3) the same implanted TAV with EOA of 1.60 cm
2 but with mild-to-
moderate paravalvular leak (Rf =17%) (Figure 3-2-c). Figure (3-2-d) shows the pressure-volume 




Figure 3-2: Examples of flow, pressure and left ventricle stroke work waveforms obtained using the model 
for; a) aortic stenosis with EOA of 0.80 cm2, with no aortic regurgitation (Rf=0%); b) transcatheter aortic 
valve with an EOA of 1.60 cm2 and no paravalvular leak (Rf=0%); c) transcatheter aortic valve with EOA 
of 1.60 cm2 but with mild-to-moderate paravalvular leak (Rf=17%); d) corresponding pressure-volume 
loops and left ventricle stroke work (LVSW). 
41 
 
TAV in both cases has successfully led to a reduction in mean transvalvular pressure 
gradient from 73 mmHg to 18 mmHg (with no PVL) and to 23 mmHg (with moderate-to-severe 
PVL). However, PVL led to a significant increase in volume overload by an increase in forward 
stroke volume from 70 mL to 86 mL. As a result, LV stroke work after TAV in the case of mild-
to-moderate PVL was not significantly different from LV stroke work prior to TAVR (1.32 .vs 
1.38 J). The TAV without PVL led to a significantly lower LV stroke volume of 1.07 J. This 
example illustrates a case where the increase in volume overload, due to PVL, counter balances 
the beneficial reduction in pressure overload. 
Table (3-2) displays the difference in LV stroke work for several possible configurations 
that can exist prior to TAVR and post TAVR in terms of EOAs and severities of aortic 
regurgitation or PVL (displayed as a color code). The values in Table (3-2) represent the 
performance index as computed using equation (7). In the majority of simulated combinations 
(76%), TAVR led to a significant decrease in LV stroke work (p<0.05). However, in 15% of cases, 
TAVR did not lead to a significant increase in LV stroke work (p>0.05) and in 9% of cases, LV 
stroke work following TAVR was significantly higher (p>0.05) than the LV stroke work pre- 
TAVR. Interestingly, most of the cases where TAVR was not successful in reducing total LV work 
overload correspond to pre-TAVR conditions with trace/mild or mild-to-moderate chronic aortic 
regurgitation and post-TAVR conditions with at least mild-to-moderate PVL.  
When investigating the performance index (PI) as computed by equation (7), it appears that 
TAVR can lead a reduction in LV stroke work up to -84±2% when a large TAV (EOA = 1.90 cm2) 
with no PVL is implanted in a very severe AS (EOA = 0.40 cm2) with initial concomitant 
moderate-to-severe aortic valve regurgitation. From another side, TAVR significantly 
underperforms if a small TAV (EOA = 1.30 cm2) with moderate-to-severe PVL is implanted in 
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Table 3-2: Differences in left ventricle stroke work for different configurations pre and post transcatheter aortic valve replacement. The values in 
the table represent the performance index as computed by (Eq. 7). 
 TAV EOA = 1.30 cm2 TAV EOA = 1.60 cm2 TAV EOA = 1.90 cm2 





























-51±6% -37±8% -21±9% -1±12% -54±6% -42±7% -28±8% -10±11% -56±6% -45±7% -32±8% -17±10% 
Mild/ 
Moderate 
-66±5% -57±7% -46±8% -31±10% -69±5% -60±6% -50±7% -38±9% -70±5% -62±6% -53±7% -43±8% 
Moderate 
-77±3% -70±4% -62±5% -52±6% -78±3% -72±4% -66±4% -57±5% -79±3% -74±4% -68±4% -60±5% 
Moderate/ 
Severe 












-32±8% -10±10% +10±12% +39±16% -36±7% -19±10% -0±11% +25±14% -39±7% -23±9% -6±10% +16±13% 
Mild/ 
Moderate 
-50±6% -36±8% -20±10% +1±12% -54±6% -41±8% -37±9% -9±11% -55±6% -44±7% -31±8% -15±10% 
Moderate 
-64±5% -54±6% -42±7% -26±9% -66±4% -57±5% -47±6% -33±8% -68±4% -59±5% -50±6% -38±7% 
Moderate/ 
Severe 












-19±9% +4±12% +31±14% +65±18% -24±8% -4±11% +20±12% +49±16% -27±8% -8±10% +13±11% +38±14% 
Mild/ 
Moderate 
-39±7% -22±9% -2±11% +24±14% -43±7% -28±9% -10±10% +12±13% -45±6% -31±8% -16±9% -4±12% 
Moderate 
-54±5% -40±7% -25±7% -5±10% -57±5% -45±6% -31±7% -14±9% -58±4% -48±6% -35±6% -21±8% 
Moderate/ 
Severe 












-10±10% +16±13% +46±15% +84±20% -15±19% +7±12% +34±13% +66±17% -18±19% +2±11% +26±12% +54±16% 
Mild/ 
Moderate 
-31±8% -11±10% +12±12% +41±15% -35±7% -18±9% +2±10% +27±14% -38±7% -22±9% -4±10% +18±12% 
Moderate 
-46±6% -31±7% -13±8% +10±11% -50±5% -36±10% -21±7% -1±10% -52±5% -39±6% -25±7% -8±9% 
Moderate/ 
Severe 
-59±5% -47±7% -34±8% -16±10% -62±5% -51±6% -39±7% -24±9% -63±5% -54±6% -43±6% -30±8% 
  LV stroke work following TAVR is significantly lower that LV stroke work before TAVR (p < 0.05) 
 No significant difference between LV stroke work before and following TAVR (p > 0.05) 
 LV stroke work following TAVR is significantly higher than LV stroke work before TAVR (p < 0.05) 
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pure borderline severe AS (EOA = 1.00 cm2) and can lead to a performance index, or a relative 
increase in LV stroke work, of +84±20%.   
Figure (3-3) shows the correlation between the computed values of the performance index 
using equation (7) and the estimated values using equation (8). There was an excellent correlation 
and concordance between the computed and estimated values (R=0.997, SEE=2.46%). 
 
Figure 3-3: Correlation between the Performance Index (PI) computed from (Eq. 7) and estimated using 




The key findings of this study are: 1) Paravalvular leak following TAVR have a significant 
negative impact on LV overload mainly when a TAV is implanted in an AS with trace/mild aortic 
regurgitation; 2) The variation in LV overload following TAVR can be well estimated non-
invasively using the TAV performance index. 
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Since the first in-man implantation of a transcatheter aortic valve by Cribier et al. (2002), 
TAVR created a paradigm shift in the way severe symptomatic aortic stenosis is treated. Several 
studies have clearly demonstrated the feasibility and advantages of TAVR in patients with high 
operative risks who are denied surgical aortic valve replacement (Leon et al., 2010; Smith et al., 
2011). TAVR led to immediate short term benefits by lowering transvalvular pressures gradients 
and an improvement in diastolic function (Clavel et al., 2009; Gonçalves et al., 2011).  
However, it has been documented that a proportion of patients did not benefit from TAVR 
in terms of prognosis or symptoms despite a clear improvement in hemodynamic conditions 
(increase in valve EOA and decrease in transvalvular pressure gradients) (Buellesfeld et al., 2011; 
Gotzmann et al., 2011b). This was mainly attributed to the presence of paravalvular leak following 
TAVR (Gotzmann et al., 2011a, 2011b). Several studies have shown that PVL moderate/severe is 
an independent predictor of in-hospital death 30 days and 1 year mortality and worsening of LV 
filling patterns (Abdel-Wahab et al., 2011; Tamburino et al., 2011; Caballero et al., 2015). Some 
studies have even shown that mild to moderate PVL can lead to limited outcome following TAVR 
(Athappan et al., 2013; Hayashida et al., 2012). Both anatomical and procedural aspects can lead 
to PVL, the most significant however, are the circularity of the aortic annulus, the level and 
location of the calcification of aortic valve leaflets and an inadequate positioning of the TAV (Ali 
et al., 2015). 
The originality of this study is that it does not evaluate PVL and TAVR outcome in terms 
of LV overload in an absolute frame of reference but relative to pre-TAVR pressure and volume 
overloads. This allowed the definition of different combinations pre-TAVR vs. post-TAVR that 
theoretically will lead to less favorable outcomes. The results show that critical conditions in terms 
of LV stroke work occur when PVLs are imposed on a LV that was mainly subjected, pre-TAVR, 
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to a pressure load (severe AS and trace/mild regurgitation). In fact, when implanted in a pure 
severe aortic stenosis (trace/mild aortic regurgitation), significant PVL (mild-to-moderate or 
moderate-to-severe) contribute to an immediate switching from a pressure overload to a volume 
overload. This can contribute to clarifying the “intriguing association” between mild PVL and 
mortality (Pibarot et al., 2015). As a consequence, patients with pure aortic stenosis (trace/mild 
regurgitation) should receive more attention when selecting the TAV to be implanted and 
implantation procedure in order to minimize PVL.  
Evaluation of changes in LV overload using TAV performance index. In this study, we 
introduced a TAV performance index that represents the relative changes in LV load (including 
pressure and volume loads) before and after TAVR. Interestingly, equation (7) can be rewritten 
under another form:  







 𝑣𝑜𝑙𝑢𝑚𝑒 𝑙𝑜𝑎𝑑 𝑟𝑎𝑡𝑖𝑜
×
(𝑃𝑠 + 𝑇𝑃𝐺𝑇𝐴𝑉̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )
(𝑃𝑠 + 𝑇𝑃𝐺𝐴𝑆̅̅ ̅̅ ̅̅ ̅̅ )⏟        
 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑙𝑜𝑎𝑑 𝑟𝑎𝑡𝑖𝑜
⏞                      











(1 − 𝑅𝑓𝑇𝐴𝑉)⏟        
 𝑣𝑜𝑙𝑢𝑚𝑒 𝑙𝑜𝑎𝑑 𝑟𝑎𝑡𝑖𝑜
×
(𝑃𝑠 + 𝑇𝑃𝐺𝑇𝐴𝑉̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )
(𝑃𝑠 + 𝑇𝑃𝐺𝐴𝑆̅̅ ̅̅ ̅̅ ̅̅ )⏟        
 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑙𝑜𝑎𝑑 𝑟𝑎𝑡𝑖𝑜
⏞                      







        (9) 
Where Rf_AS and Rf_TAV represent the regurgitant fraction (before and after TAVR, 
respectively (see appendix A for details). It appears then that a high TAV performance index is 
achieved for very small LV stroke work load ratios (ratio between LV load post-TAVR over LV 
load pre-TAVR). Then, if PVL severity post-TAVR is more significant than the pre-existing 
regurgitation severity pre-TAVR (volume load ratio > 1) then for TAVR to be beneficial it has to 
lead to a substantial decrease in pressure load ratio (reduction in mean transvalvular pressure 
gradient). This explains why a larger number of adverse conditions following TAVR are obtained 
in this study when a TAV with an EOA of 1.30 cm2 was implanted in a severe aortic stenosis of 
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1.00 cm2: the reduction in pressure load ratio was simply not sufficient to counterbalance the 
increase in volume load ratio due to more than mild PVL. Finally, note that the performance index 
as defined can also be used with other procedures that may result in aortic regurgitation like balloon 
valvuloplasty (Cribier et al., 1987) or surgical valve replacement, although aortic regurgitation is 
now occasionally occurring.  
 
3.5. Limitation 
In this work the mathematical modeling did not incorporate potentially unrecoverable 
myocardial remodeling and contractile dysfunction. This obviously could enter in play in real life 
situations that need to be accounted for in future studies. Depressed myocardial function may in 
part profile a lower left ventricular to aortic pressure gradient prior to valve replacement. In such 
cases, PVL may be deleterious to cardiac work load even in the low grade secondary Rf situations. 
On the other hand, beyond the degree of the PVL in terms of effective cardiac output, the 
interplay between a lower aortic diastolic pressure secondary to the TAVR and the effective 
coronary artery flow need to be taken into consideration, especially in the elderly patient with 
coronary artery lesions and atherosclerosis.  
 
3.6. Conclusion 
Transcatheter aortic valve replacement is a viable solution for symptomatic patients with 
severe aortic stenosis who are denied surgical aortic valve replacement because of elevated 
operative risks. However, the beneficial results might be suboptimal due to the presence of 
paravalvular leak. This study shows that patients with severe aortic stenosis and trace/mild aortic 
regurgitation are those that would benefit the least from transcatheter aortic valve replacement 
with subsequent paravalvular leak, despite a reduction in aortic pressure gradients. This population 
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should be considered with care when planning for transcatheter aortic valve replacement. Finally, 
a new non-invasive parameter has been introduced to estimate the performance of transcatheter 
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Transcatheter aortic valve replacement has emerged as an alternative option in high 
surgical risk patients with severe symptomatic aortic stenosis. However, paravalvular leak still 
represents a significant complication. This study aims at using 3D numerical simulations to 
investigate the effect of paravalvular leak on diastolic flow-field characteristics following 
transcatheter aortic valve replacement. 
We show that paravalvular leak leads to significant disturbances in blood flow 
characterized by high speed jets, small and large scale coherent structures and markedly elevated 
shear stress on both sides of the implanted aortic leaflets. Such unfavorable flow configuration 







Transcatheter aortic valve replacement (TAVR) has emerged as the preferred therapeutic 
intervention for inoperable patients with severe symptomatic aortic stenosis and as an alternative 
option in high surgical risk individuals (Leon et al., 2010; Smith et al., 2011). However, data from 
multiple registries and trials with different valve designs have shown that TAVR is associated with 
various complications in approximately one third of cases (Fishbein et al., 2013). 
One of the major TAVR related complications is paravalvular leak (PVL) (Dvir et al., 
2013). The prevalence of PVL varies among different studies and can range from 7% to 70% for 
mild PVL and 0% to 24% for more a than moderate PVL (Pibarot et al., 2015). PVL leads to 
volume overload and increased stroke work of the stiff, non-compliant left ventricle (Bekeredjian 
and Grayburn, 2005). As a consequence, PVL has been shown to be an independent predictor of 
short-term and long-term mortality following TAVR (Moat et al. 2011; Tamburino et al. 2011; 
Abdel-Wahab et al. 2011; Kodali et al. 2012).  
Despite its clinical significance, only few studies addressed specifically the hemodynamic 
effect of PVL after TAVR (Genereux et al. 2013). From a fluid dynamics point of view, different 
numerical studies have investigated flow through different types of transcatheter valves (Dwyer et 
al. 2009; Quail and Taylor 2013; Sirois et al. 2011). However, little is known regarding flow 
patterns induced by PVL following TAVR.  
The objective of this numerical study was to investigate the effect of PVL on diastolic 
flow-field characteristics using 3D numerical simulations. The results of this study will be of 






4.2.1. Geometrical Model 
Figure (4-1) shows the schematic diagram of the model used in this study. The anatomical 
model includes the left ventricular outflow tract (LVOT), the sinuses of Valsalva, the aortic root 
and the proximal ascending aorta (Keshavarz-Motamed et al., 2013) (Figure 4-1-a). An Edwards 
SAPIEN 26 mm transcatheter aortic valve was simulated. It consists of a trileaflet bovine 
pericardial tissue valve embedded on a stainless steel metallic stent frame and within a tissue skirt 
(Figure 4-1-b) (Auricchio et al., 2014). See appendix B, figure (B-1) for more details. 
 
Figure 4-1: Geometry considered for numerical simulations. (a) Simulation domain; (b) Transcatheter 




PVL was modeled by creating three different orifices at the level of the aortic root (with 
areas of 1 mm2, 4 mm2 and 20 mm2, respectively) (Fig. 1c and 1d). The size and the shape of the 
orifices correspond to the smallest, the median and the largest regurgitant orifice areas (ROA) 
obtained in vivo by Hahn et al. (Hahn et al., 2013). Both regular and irregular PVL orifice shapes 
were considered. All were located in the middle of the cusps (see Fig. 1c), where a high 
concentration of calcium is usually found in severe aortic stenosis (Sinning et al., 2013). 
 
4.2.2. Numerical Model 
PVL can lead to regions of disturbed flow both upstream and downstream of the 
transcatheter aortic valve. This in turn generates turbulence during both parts of the cardiac cycle 
(i.e., Re>1000) (Ryval et al. 2004). The k--SST model is well adapted to simulate low-Re internal 
flows (Re < 10,000) and was therefore used in our study. This model has also been shown to give 
a good overall representation of both steady and pulsatile flow and has been validated in blood 
flow studies where both laminar/transitional and turbulent flow regimes coexist (Ghalichi et al. 
1998; Ryval et al. 2004;Keshavarz-Motamed & Kadem 2011; Keshavarz-Motamed et al. 2013). 
The model was meshed using tetrahedral elements (Appendix B, figure (B-2)). The grid 
was also clustered at the valve region and additional care was taken to maintain y+ <1 for high 
quality wall treatment by k--SST
 
model for low-Re flows. Mesh independency was evaluated 
based on the results of both velocity magnitude and valve wall shear stress (WSS). A total number 
of 3,794,696 tetrahedral elements were used for the final simulations. The solution marched in 
time with a time step of 0.001 s to satisfy time independency. The convergence was obtained when 
all residuals reached a value lower than 10-5. Computations were performed using commercially 
available computational fluid dynamics software (ANSYS Fluent v14.0). 
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CFD uncertainty was analyzed considering wall shear stress values as output parameter 
(Table 4-1) (Celik et al. 2008). The parameters,  , ext , ae , exte  and fineGCI  represent the wall 
shear stress, the extrapolated wall shear stress value, the approximate relative error, the 
extrapolated relative error and the fine-grid convergence index, respectively. For the analysis, 
WSS was determined at two locations on the valve leaflets close to the smallest and largest 
regurgitant orifices (see Points A and B in Table 4-1). The computations indicate that the numerical 
uncertainties on wall shear stress are 2.69% and 5.83%.  
 
Table 4-1: Calculation of discretization errors for the simulation at two regions: A and B. 
.ø (wall shear stress), øext (the extrapolated wall shear stress value),ea (approximate relative error), eext 
(extrapolated relative error)and GCIfine(fine-grid convergence index). 
 
 Point A Point B 
 


















Additionally, to account for the temporal oscillations in wall shear stress the oscillatory 
















Where T and τ are the duration of diastole cycle and total instantaneous wall shear stress, 
respectively. OSI can reach a maximum value of 0.5 in regions with high oscillating shear stress 
that are prone to atherosclerosis.  
 
4.2.3. Boundary Conditions and Model Properties 
Blood was assumed to be a Newtonian and incompressible fluid with dynamic viscosity of 
0.0035 Pa.s and a density of 1050 kg/m3, a valid assumption for flows in large cavities and arteries      
(Fung 1981; Kuan & Espino 2014; Xenos et al. 2013; Gramigna et al. 2014). The arterial wall was 
treated as solid and rigid. This can be justified by: (1) patients with severe aortic stenosis who can 
be candidate for TAVR have reduced arterial compliance (Briand et al., 2005); (2) Jin et al. (2003) 
showed that rigid wall assumption for the aorta is realistic. Their results showed that the overall 
behavior for wall shear stress at each point is similar for the rigid and elastic walls with average 
root mean squared error of 1.23%; (3) Keshavarz-Motamed et al. (2013) performed joint 
experimental magnetic resonance imaging (MRI) and numerical investigations for different 
models of the aorta, including normal aorta. There was a good agreement between numerical 
simulations on rigid aortas and MRI velocity measurements on elastic aortas.  
This study focuses on diastole, the filling phase of the left ventricle, during which PVL 
occurs. Therefore, the aortic valve leaflets were modeled to be rigidly closed. A non-permeable 
and no-slip boundary condition was applied at the rigid walls. A velocity waveform was imposed 
at the ascending aorta (Figure 4-2) and an outflow boundary condition was applied at the exit. The 
diastolic velocity waveform applied at the inlet of the model was obtained from phase contrast 
magnetic resonance imaging measurements performed by Hayek et al. (2014) in a patient with 
PVL. This corresponded to maximum diastolic Reynolds numbers of 934 at the inlet and 6300 in 
the PVL regions. The computed regurgitant fraction was 35%. As a consequence, the simulations 
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deal with a mild/moderate (grade II) PVL. This PVL grade was frequently observed in patients 
who underwent TAVR using the SAPIEN valve (30% of patients) or the newest valve design 
SAPIEN XT valve (42% of patients) (Amat-Santos et al., 2015). 
 
 
Figure 4-2: Velocity waveform used as inlet boundary condition for the numerical simulations based on 





Figure (4-3) displays different 2D and 3D views of multiple iso-surfaces of velocity 
magnitude in three different instants during diastole: peak diastolic regurgitant flow (0.358 s), mid-
diastolic regurgitant flow (0.590 s) and the end diastolic regurgitant flow (0.858 s). Three high 
speed jets were generated through the regurgitant orifices. The velocity of the jets rapidly increased 
during early diastole to reach a maximum velocity. At the peak of diastolic regurgitant flow, peak 
velocities were 4.13 m/s for the 20 mm2 orifice, 3.18 m/s for the 4 mm2 orifice and 2.33 m/s for 
the 1 mm2 orifice. This is followed by a continuous decrease in orifice jet velocities as a result of 




Figure 4-3: Different 2D 
and 3D views (top, right, 
left and a horizontal 
cross-section) of velocity 
magnitude iso-surfaces 
at three instants t=0.358 
s, t= 0.590 s and t= 
0.858 s; A-A) 3D left-
side view of velocity 
magnitude iso-surfaces; 
B-B) 3D right-side view 
of velocity magnitude 
iso-surfaces; C-C) 3D 
velocity magnitude 
contours and their 
projections on the cross 





Figure (4-4) shows velocity magnitude contours and streamlines at two different 
longitudinal cross sections for the same instants as in Figure (4-3). The presence of three 
regurgitant orifices leads to an asymmetric flow in the proximal aorta and in the LVOT region. 
This asymmetry generates coherent structures in the flow field. In the ventricular side, at the peak 
of regurgitant flow, the high speed jets create large recirculation zones in the LVOT region. Theses 
coherent structures are rapidly convected downstream during diastole, leaving just a vortex 
structure just below the aortic valve leaflets (Panel B, Section EE). By the end of diastole, no major 
coherent structures are present in the LVOT region. In the proximal aortic side, at the peak of 
regurgitant flow (Panel A, Section EE), the asymmetry of regurgitant orifice positions leads to 
vortex shedding from the valve leaflet coaptation region. During the remaining diastole, the sheded 




Figure 4-4: Two cross-
sectional views of velocity 
magnitude and stream 
lines at three instants 
t=0.358 s, t= 0.590 s and 
t= 0.858 s; E-E) 2D view 
of velocity magnitude 
contours on a plane 
crossing both orifices of 
20 mm2 and 4 mm2 with 
symmetrical view of two 
leaflets; F-F) 2D view of 
velocity magnitude 
contours on a plane 
crossing both orifices of 4 
mm2 and 1mm2 with 





Figure (4-5) displays the oscillatory shear index (OSI) at two different cross sections in the 
LVOT region {section (G-G) and (H-H)}. Section G-G is located just upstream of the valve stent. 
While section H-H is located 1 cm below the valve stent. Just below the stent, elevated OSI values, 
close to 0.5, can be found in the regions near the larger orifices (20 mm2 and 4 mm2). Further 
below, OSI values significantly decrease for largest orifices while they increase for the smallest 
orifice 1 mm2.  
 
Figure 4-5: Oscillatory wall shear stress (OSI) on two different cross-sections in the LVOT. Section G-G 
is located just upstream of the valve stent and section H-H is located 1 cm below the valve stent. 
 
Figure (4-6) displays WSS on both sides of the valve leaflets, aortic side (Panel A) and left 
ventricle side (Panel B) at the peak of the regurgitant flow (t = 0.358 s). In the aortic side (Panel 
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A), it can be observed that the asymmetrical flow caused by PVL leads to elevated WSS, up to 
3.05 Pa, around the coaptation area of the leaflets. In addition, high localized WSS exist even on 
the left ventricular side close to the location of the regurgitant orifices (Panel B). The highest value 
of WSS (11.05 Pa) is located close to the regurgitant orifice of 4 mm2. 
 
Figure 4-6: (a) Aortic valve leaflets (aortic side) top and isometric view of wall shear stress contours at t 
= 0.358 s; (b) Aortic valve leaflets (left ventricle side) top and isometric view of wall shear stress 





This study adds significant new knowledge to our understanding of the pathophysiology 
of paravalvular leak post transcatheter aortic valve replacement. First, paravalvular leak 
significantly disturbs flow both upstream and downstream of the implanted aortic valve during 
diastole. Also PVL not only leads to elevated wall shear stress on the aortic side of the valve 
leaflets, but also on the ventricular side. 
Transcatheter aortic valve replacement has been shown to prolong survival in symptomatic 
patients with severe aortic stenosis who are not eligible for surgical valve replacement and has 
become the new standard of care. Although, TAVR provides a significant number (33%) of 
inoperable elderly patients with a life prolonging treatment option (Iung et al., 2005), it is still 
associated with some complications, with PVL being one of the most significant (Genereux et al., 
2013; Haensig et al., 2012; Schultz et al., 2009; Unbehaun et al., 2012). In high risk operative 
candidates, TAVR and surgical aortic valve replacement (SAVR) have been shown to have similar 
mortality, reduction in symptoms, and improved valve hemodynamics in the short term post 
procedure period. PVL however was significantly more prevalent in patients undergoing TAVR 
than SAVR (6.8% vs. 1.9%). Significant PVL post TAVR is a finding associated with increased 
long term morbidity and mortality. 
From a hemodynamic standpoint, PVL is associated with high speed jets emerging from 
the ascending aorta towards the LVOT region during diastole. Velocity contours show that high 
speed jets generated by PVL could reach up to 4.13 m/s for a total effective regurgitant orifice area 
of 25 mm2. This value is consistent with in vivo Doppler echocardiographic findings of  4.51 m/s 
in a patient with a total regurgitant orifice area of 26 mm2 (Hayek et al., 2014). According to 2D 
velocity contours (Figure 4-3), the jets emerging from the regurgitant orifices rapidly diverge 
61 
 
within the LVOT. This represents a significant clinical implication since the evaluation of 
paravalvular leak can be performed by a delineation of the regurgitant jet vena contracta using 2D 
transthoracic echocardiographic color Doppler or cardiac magnetic resonance imaging (Goncalves 
et al. 2012; Hayek et al. 2014). As a consequence, the location of the cross-sectional measurements 
might lead to significant errors in the determination of the effective regurgitant orifice area.  
Our study also demonstrates that paravalvular leak leads to elevated shear stress on the 
LVOT wall as well as on both sides of the valve leaflets. In the proximal ascending aorta, several 
recirculation zones are developed around the aortic valve. This unfavorable flow configuration 
leads to abnormally high shear stress values during diastole. This is an important finding, since it 
is well documented that changes in shear stress alter the biosynthetic behavior of aortic valve cells 
and can up-regulate pro-inflammatory markers in aortic valve tissues (Balachandran et al., 2011; 
Sucosky et al., 2009). Furthermore, several studies have already shown that high mechanical shear 
stress is a significant determinant of structural deterioration of bioprosthetic valve leaflets (Nobari 
et al., 2013). As a consequence, PVL in the setting of TAVR might lead to a rapid structural 
deformation of the transcatheter valve leaflets and subsequently to a reduction in valve durability.  
Finally, it is also interesting to note the differences between aortic regurgitation (through 
valve leaflet commissures) and paravalvular leak following TAVR. Native aortic valve 
regurgitation is often characterized by somehow a central jet entering the LV cavity and interacting 
directly with the mitral inflow. The jet may not be deflected towards the LVOT wall and minimally 
interacts with mitral valve leaflets. On the other hand, paravalvular leak following TAVR is 
characterized by multiple jets along the LVOT wall (Pibarot et al., 2015). This specific 
characteristic of paravalvular leak may lead to significant adverse effects on the cardiac structures 
(Figure 4-6 and 4-7) by: 1) increasing the shear stress on TAV leaflets (leading potentially to 
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decreased durability); 2) increasing the shear stress in the LVOT area; 3) directly impacting the 
mitral valve leaflets and potentially generating elevated localized shear stress. 
 
Figure 4-7: Schematic representation of the difference between (a) Native aortic valve regurgitation and 
(b) Paravalvular leak post transcatheter aortic valve replacement. 
 
4.5. Limitation  
 
In this numerical study, the simulations were performed using a SAPIEN valve. This valve 
is currently not available anymore in the market, as it has been replaced by two newer generation 
valves, the SAPIEN XT and the SAPIEN 3. The overall hemodynamic profile of the SAPIEN XT 
valve is not significantly different from the SAPIEN. Most of the improvements were regarding 
frame geometry, reduction in metal content, and a lower crimp profile. The prevalence of 
mild/moderate PVL with SAPIEN XT was still at the same level as the original SAPIEN valve 
(42% of patients) (Amat-Santos et al., 2015). However, the new SAPIEN 3 including an external 
cuff at the bottom of the valve stent to prevent PVL is showing very promising results. In a recent 
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study, Amat-Santos et al. (2015) showed that the prevalence of mild/moderate PVL was 
significantly reduced (7%) using the SAPIEN 3 valve without negatively impacting transvalvular 
pressure gradients.  
These positive results have however to be considered with caution at the moment because 
of the small sample size and the absence of an accurate quantitative method for evaluating PVL. 
Finally, this study does not consider the anatomical shape of the LV cavity below the LVOT 





Paravalvular leak following transcatheter aortic valve replacement leads to significant 
disturbance in blood flow characteristics both upstream and downstream of the implanted valve. 
The abnormal flow is characterized by high speed jets, small and large scale coherent structures 
and markedly elevated shear stress on both sides of the implanted aortic leaflets. Such unfavorable 
flow configuration may promote a more rapid degeneration of the transcatheter valve leaflets.  
 
 
4.7. Additional Results and Discussions 
 
In addition to the results which are presented in section (4.3), some results are extracted 
and presented in this chapter on flow characteristics. 
Figure (4-8) represents the evolution of the secondary flow in three different sections below 




Figure 4-8: Evolution of the secondary flow during diastole cycle at 6 instants. A-A) Section right below 
the valve stent in left ventricular side; B-B) Section 1 cm below the valve stent; C-C) Section 3 cm below 
the valve stent 
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It appeared that as a result of high speed PVL jets, rotating vortices developed in the left 
ventricular side (highest secondary flow velocity = 1.2 m/s). Abnormal flow conditions persist so 
close to the left ventricular walls explaining the elevated wall shear stress distribution at the LV 
inner wall. 
Figure (4-9) shows the evolution of the Lambda-2 Criterion. Lambda-2 is a method 
introduced by Jeong and Hussain (1995) for visualization and extraction of flow vortices 
(Appendix C).  
 
Figure 4-9: Lambda-2 Evolution during Diastole 
  
As it could be seen from the figure different vortical structures are developed during the diastole 
and persist till the end of the diastole. . The adverse effect of the small and large scale vortices on 





CHAPTER 5: Conclusion and Summary 
 
In this study, first a mathematical lumped parameter model which was previously validated 
by (Keshavarz-Motamed et al., 2011) is used to model several patient conditions with pre-TAVR 
aortic stenosis and post TAVR paravalvular regurgitation with different level of severities. The 
performance of TAVR is evaluated considering the relative change in the computed left ventricle 
stroke work (LVSW). In addition, a new non-invasive parameter (TAVR-PI) is introduced to 
estimate the efficiency of transcatheter aortic valve replacement in reducing left ventricle work 
overload. Results show that patients with severe aortic stenosis and trace/mild aortic regurgitation 
should be considered with care when planning for TAVR due to the potential suboptimal 
performance of TAVR.  
Future studies could also consider the effect of myocardial remodeling and contractile 
dysfunction due to the presence of the stenosis pre-TAVR, which could increase the risk of post-
operative complications and mortality. 
Second, a computational fluid dynamic model is performed to study the hemodynamics of 
the transcatheter aortic valve (TAV) in presence of the paravalvular leak (PVL). A realistic 
geometry of TAV, and turbulent computational fluid (k--SST) model are employed and in-vivo 
boundary condition applied to simulate the PVL during diastole cycle. Results show that PVL 
following TAVR significantly disturbs blood flow characteristics both upstream and downstream 
of the TAV. High speed jets, small and large scale coherent structures and drastically elevated 
shear stress on both sides of the TAV aortic leaflets are seen, which could promote a more rapid 
deterioration of the transcatheter valve leaflets. 
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Future studies, could address the 3rd generation of TAVs such as SAPIEN3, since little is 
known on flow characteristics of these new generation of the valves. Furthermore, future 
simulations should investigate the interaction between PVL and diastolic inflow and potentially 
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The lumped model illustrated in figure (3-1) was analyzed numerically by creating and solving a 
system of ordinary differential equations in Matlab Simscape (MathWorks, Inc). A Fourier series 
representation of an experimental normalized elastance curve for human adults was used as input 
to the main program (Senzaki et al., 1996).  
Simulations were started at the onset of isovolumetric contraction. The left ventricle 
volume V(t) was calculated using the left ventricle pressure PLV and elastance values. The PLV used 
at the beginning of the calculation was the initial value assumed across the variable capacitor and 
was automatically adjusted later by the system of equations as the solution advances. The left 
ventricle flow rate subsequently was calculated as the time derivative of the left ventricle volume. 
A diode with very low on resistance and off conductance was used in the aortic valve to prevent 
backflow from the valve. The same concept was used for aortic valve regurgitation.  
Matlab’s “ode23t” trapezoidal rule variable-step solver was used to solve the system of differential 
equations with an initial time step of 0.1 milliseconds. The convergence residual criterion was set 
to 10−5 and the respective initial voltages and currents of the capacitors and inductors were set to 
zero. 




















In 1995, Jeong and Hussain introduced a new computational method for identifying the vortex 
regions and cores based on the pressure minimum. Among the different vortex core character 
definitions, this definition is found to represent the topology and geometry of vortex cores correctly 
for the large variety of flows. The proposed method known as Lambda-2 criterion is now widely 
in use by scientists and engineers. This appendix represents a short review on the method and 
equations. 
Pressure minimum itself cannot be used as a general detection criterion for a vortex core due to 
two effects: (1) unsteady straining, which can create a pressure minimum without a vortical 
motion, and (2) viscous effects, which can eliminate the pressure minimum in a flow with vertical 
or swirling motion. However, pressure minimum provides a good starting point for a new 
definition. Therefore, by discarding the contributions of unsteady irrotational straining and 
viscosity, we expect to obtain a better indicator for the existence of a vortex.  
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The antisymmetric part (second part) is the well-known vorticity transport equation. Considering 










The occurrence of a local pressure minimum in a plane requires two positive eigenvalues of the 
tensor. Here, as argued above, we will not consider the first two terms in the left-hand side of (3) 
since the first term represents unsteady irrotational straining and the second term represents 
viscous effects. Thus, we consider only Ω2 + 𝑆2 to determine the existence of a local pressure 
minimum due to vortical motion and define a vortex core as a connected region with two negative 
eigenvalues of Ω2 + 𝑆2. Note that since Ω2 + 𝑆2 is symmetric, it has real eigenvalues only. If 
𝜆1, 𝜆2 and 𝜆3 , are the eigenvalues and𝜆1 ≫ 𝜆2 ≫ 𝜆3  the new definition is equivalent to the 
requirement that 𝜆2< 0 within the vortex core. 
The identification of the vortex is summarized in the table below. 
 
Table C-1: Vortex identification, Lambda-2 criterion 
     𝝀𝟏         𝝀𝟐         𝝀𝟑          ∑𝝀𝒊 
Negative  𝝀𝟐  
+           -           -            - Vortex core 
+           -           -            + Vortex core 
+           +           -           - Note vortex core 
 +           +          +            + Not vortex core 
 
 
